Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CBN Spirulina Canada is a biotechnology and nutraceutical company specializing in the cultivation and processing of high-quality spirulina (Arthrospira platensis). The company operates a controlled indoor production facility in Canada, utilizing proprietary technology to ensure the purity and nutrient density of its algae products. Their primary offerings include spirulina powder and tablets marketed for their antioxidant, anti-inflammatory, and immune-boosting properties. By focusing on closed-loop systems, the company aims to provide a contaminant-free alternative to traditionally pond-grown spirulina. CBN Spirulina Canada serves both the direct-to-consumer health market and the broader food and beverage industry as a functional ingredient supplier.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on C.B.N. Spirulina Canada.